Stock NKGN NKGEN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 18:00:00 2024-05-22 EDT 		5-day change 1st Jan Change
1.86 USD +4.49% Intraday chart for NKGen Biotech, Inc. +5.68% -32.36%
05-23 NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting CI
05-20 Sector Update: Health Care Stocks Softer Late Afternoon MT

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 - - 60.19
Enterprise Value (EV) 1 - - 80.09
P/E ratio -5.94 x -5.79 x -0.51 x
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA - - -2.81 x
EV / FCF - - 7,077,483 x
FCF Yield - - 0%
Price to Book -3.63 x 207 x -1.03 x
Nbr of stocks (in thousands) - - 21,889
Reference price 2 9.690 9.950 2.750
Announcement Date 23-08-04 23-08-04 24-04-16
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 0.426 0.077 -
EBITDA 1 -20.73 -23.14 -28.54
EBIT 1 -21.86 -24.35 -29.75
Operating Margin -5,131.69% -31,618.18% -
Earnings before Tax (EBT) 1 -23.26 -26.75 -82.95
Net income 1 -23.26 -26.75 -82.95
Net margin -5,461.27% -34,745.45% -
EPS 2 -1.633 -1.719 -5.377
Free Cash Flow - -16.5 11.32
FCF margin - -21,426.62% -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 23-08-04 23-08-04 24-04-16
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 51.6 11.9 19.9
Net Cash position 1 - - -
Leverage (Debt/EBITDA) -2.49 x -0.5151 x -0.697 x
Free Cash Flow - -16.5 11.3
ROE (net income / shareholders' equity) - 147% 290%
ROA (Net income/ Total Assets) - -88.5% -113%
Assets 1 - 30.24 73.2
Book Value Per Share 2 -2.670 0.0500 -2.680
Cash Flow per Share 2 0.0200 0 0
Capex 1 0.4 0.1 -
Capex / Sales 94.6% 131.17% -
Announcement Date 23-08-04 23-08-04 24-04-16
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NKGEN BIOTECH, INC. Stock NKGen Biotech, Inc.
-32.36% 33.36M
MODERNA, INC. Stock Moderna, Inc.
+54.05% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.02% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+40.01% 40.47B
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.17B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.42% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.60% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.89% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.40% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.49% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NKGN Stock
  4. Financials NKGen Biotech, Inc.